Infliximab reverses growth hormone resistance associated with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 9, 2005, Pages 1063-1071

  Vespasiani Gentilucci, U ^a   Caviglia, R ^b   Picardi, A ^a,b   Carotti, S ^b   Ribolsi, M ^b   Galati, G ^a   Petitti, T ^b   Afeltra, A ^a   Cicala, M ^b  

^a Interdisciplinary Center for Biomedical Research CIR   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BILE ACID; C REACTIVE PROTEIN; GROWTH HORMONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DRUG EFFECT; DRUG INFUSION; ENTERITIS; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; WASTING SYNDROME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED;

EID: 18444379959     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02449.x     Document Type: Article

References (43)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
2. Chong SK, Bartram C, Campbell CA, Williams CB, Blackshaw AJ, Walker-Smith JA. Chronic inflammatory bowel disease in childhood. Br Med J 1982; 9: 101-3.
3. Seidman E, LeLeiko N, Ament M, et al. Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 424-38.
4. Lundsgaard C, Hamberg O, Thomsen OO, Nielsen OH, Vilstrup H. Increased hepatic urea synthesis in patients with active inflammatory bowel disease. J Hepatol 1996; 24: 587-93.
5. Goh J, O'Morain CA. Review article: Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 307-20.
6. Koniaris SG, Fisher SE, Rubin CT, Chawla A. Experimental colitis impairs linear bone growth independent of nutritional factors. J Pediatr Gastroenterol Nutr 1997; 25: 137-41.
7. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition. in a rat model of colitis. Gut 2000; 46: 694-700.
8. Wolf M, Bohm S, Kreymann MB, Kreymann G. Proinflammatory cytokines interleukin-1β and tumor necrosis factor ζ inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rats liver cells. Eur J Endocrinol 1996; 135: 729-37.
9. Lelbach A, Scharf JG, Ramadori G. Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein-1, -3 and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J Hepatol 2001; 35: 558-67.
10. Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-I and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995; 269: 1204-12.
11. Picardi A, Gentilucci UV, Zardi EM, et al. TNF-alpha and growth hormone resistance in patients with chronic liver disease. J Interferon Cytokine Res 2003; 23: 229-35.
12. Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 1986; 91: 830-6.
13. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001; 11: 364-7.
14. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
15. Theiss AL, Fruchtman S, Lund PK. Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm Bowel Dis 2004; 10: 871-80.
16. Baxter RC. The somatomedins: insulin-like growth factors. Adv Clin Chem 1986; 25: 49-115.
17. Beattie RM, Camacho-Hubner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol 1998; 49: 483-9.
18. Gronbek H, Thogersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF. Low free and total insulin-like growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol 2002; 97: 673-8.
19. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
20. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336; 16-9.
21. Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet 1980; 8178: 1134-5.
22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
23. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2577-84.
24. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342: 1633-7.
25. Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989; 97: 905-10.
26. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 373-80.
27. Murch SH, Lamkin VA, Savage MO. Walker-Smith JA, Mac-Donald TT. Serum concentrations of tumour necrosis faetor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
28. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
29. Gotlin RW, Dubois RS. Nyctohemeral growth hormone levels in children with growth retardation and inflammatory bowel disease. Gut 1973; 14: 191-5.
30. Farthing MJ, Campbell CA, Walker-Smith J, Edwards CR, Rees LH, Dawson AM. Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut 1981; 22: 933-8.
31. Fan J, Li YH, Bagby GJ, Lang CH. Modulation of inflammation-induced changes in insulin-like growth factor (IGF)-I and IGF binding protein-1 by anti-TNF antibody. Shock 1995; 4: 21-6.
32. Lang CH, Fan J, Cooney R, Vary TC. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol 1996; 270: 430-7.
33. Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156-64.
34. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463-73.
35. Cellier C, Sahmoud T, Froguel E, et al. (The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives). Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994; 35: 231-5.
36. Saverymuttu SH, Camilleri M, Rees H, Lavender JP, Hodgson HJ, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986; 90: 1121-8.
37. Tibbie JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
38. Schreiber S, Nikolaus S, Hampe J, et al. Tumor necrosis lector alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-61.
39. Ghosh S, Drummond HE, Ferguson A. Neglect of growth and development in the clinical monitoring of children and teenagers with inflammatory bowel disease: review of ease records. BMJ 1998; 317: 120-1.
40. Gee MI, Grace MG, Wensel RH, Sherbaniuk R, Thomson AB. Protein-energy malnutrition in gastroenterology outpatients: increased risk in Crohn's disease. J Am Diet Assoc 1985; 85: 1466-74.
41. Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 2003; 26: 799-813.
42. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res 2002; 58: 33-8.
43. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36: 342-7.